QSC Tirzepatide 5mg Peptide - High Purity GLP-1/GIP Receptor Agonist for Research

QSC Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This peptide demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.

The QSC Tirzepatide formulation shows particular affinity for GIP receptors while maintaining significant GLP-1 receptor activity. This unique dual mechanism has been shown to produce more substantial reductions in hyperglycemia in research settings. The molecular structure of QSC Tirzepatide allows it to effectively mimic the actions of natural GIP at receptor sites.

Our QSC Tirzepatide is supplied as a high-purity white powder with pharmaceutical-grade quality standards. Each batch undergoes rigorous HPLC testing to ensure consistent purity and performance characteristics. The product is carefully packaged to maintain stability during storage and transportation.

For research purposes, QSC Tirzepatide represents an important tool for studying metabolic disorders and potential therapeutic interventions. Its dual-receptor activity provides unique opportunities for investigating novel treatment approaches in diabetes research.

Note: This product is supplied for research use only, not for human consumption. Proper handling and storage procedures should be followed to maintain product integrity.